Endotherapia (GEMSP) is a novel therapeutic approach for multiple sclerosis (MS). The aim of the present Status Scale (EDSS) score, which is a functional scale of MS progression. The evaluated score of each patient during follow-up visits was compared with the theoretical score of the disease progression without GEMSP. The evolution of the EDSS score was evaluated according to the inclusion worldwide reference (R) groups. The improvement of the M group compared with the R group was 24.5%. According to to the qualitative evolution of the EDSS scores, the improvequalitative study of the EDSS score showed a statistically significant success percentage; the success percentages that were previously reported in pre-clinical and clinical or deceleration of the disease.
Introduction
ating and neurodegenerative disease that predominantly affects facilitate the movement of auto-reactive T cells and demyelin-To date, MS has no cure and only partially efficient and laquinimod]. None of these therapeutic agents reduce Thus, novel therapeutic strategies and agents are required for the treatment of MS (5) . One such therapeutic strategy/agent neurodegenerative and auto-immune diseases) that accounts immunological factors. This includes the identification of use of therapeutic tools, such as small compounds linked to the carrier poly-L-lysine (PLL) and the physiological actions found during the course of MS, the chemical composition and lished for each patient (9) .
GEMSP was originally conceived for the treatment of tion of amino acids, fatty acids, free radical scavengers and mental autoimmune encephalomyelitis (EAE) models (10,11). unchanged in 55% (1) . Due to the promising results found in
Follow-up of multiple sclerosis patients treated with Endotherapia (GEMSP)
preclinical and clinical studies, another study with a larger The present study follows up the evolution of the disease in a treatment.
Materials and methods
Population description. The present study was performed (21.2%)]. The patients provided written informed consent and mental unit was the patient. The EDSS score (9) was evaluated, and treatment with GEMSP (M) and worldwide reference (R) uated in each patient following clinical evaluation, whereas the R score was the estimated theoretical international score evolution (0.25 points/year/patient). The period of treatment collected: Age, gender, date of diagnosis, start/termination of GEMSP treatment and the MS Assessment Questionnaire follow-up for each patient over time. In addition, the evolution of the EDSS score was tracked during the study. A plot of the evolution of the EDSS score (R) over time was conducted.
of EDSS evolution (0.25 point/year), allowing the evolution of trend of progression. Finally, the duration of the GEMSP treat-
Score.
In order to assess the total effect of treatment with GEMSP for each patient, the individual mean of EDSS evolution was determined over time as follows: i) When the individual mean rate of EDSS evolution with GEMSP was greater or equal to the mean speed of the worldwide EDSS reference, this indicated disease progression (a worsening of the state of the patient); ii) when the individual mean rate of EDSS evolution the worldwide EDSS reference and 0, this indicated a decrease in the progression of the disease; iii) when the individual mean rate of EDSS evolution with GEMSP was equal to 0, this indievolution of the disease was reversed (an improvement of the disease and a recovery from lesions occurred).
Statistical analysis.
of the MS cohort included in the current study, a method of Thus, the Mann-Whitney U test was used to compare the the score evolution of each patient was compared with the worldwide reference score (R)], allowing the comparison of with GEMSP. P<0.05 was considered to indicate a statistically significant difference and analyses were performed using the SAS Institute Inc., version 9 software (Cary, NC, USA); to confirm that the statistics were correctly conducted. A comprehensive study of the EDSS score and the EDSS evolution was conducted. In the descriptive analysis, the following tion, minimum, 1 st quartile, median, 3 rd descriptive analysis the following parameters were evaluated:
Furthermore, a qualitative study of the EDSS score following parameters were evaluated: Strength, percentage /failures rates: The 2 (% success > % failure).
Dose and synthesis of GEMSP. GEMSP (15 mg per day) was polypeptides: Fatty acids linked to PLL (e.g., thioctic acid, to PLL (e.g., taurine, cysteine and methionine).
Results

General considerations.
Patients included in the current study EDSS global study. A statistically significant difference of the M group was 4.44 and that of the R group was 5.43. Regarding the EDSS mean score upon inclusion in the study, the R group the increase was 24.5%. In 193 patients treated with GEMSP, 22% showed a worsening of their state (degradation); 51% showed a decrease in the progression of the disease -ment or deceleration of the disease ( Fig. 2A) . The difference EDSS score depending on the score upon inclusion in the study. A statistically significant difference was identified in comparison with the EDSS inclusion scores, the percentages of improvement for the M group were as follows: 62% the qualitative evolution of the EDSS scores, a statistically not in the case of score 3-6. The percentages of improvement did not respond to the therapy and evolution follows the R score. Deceleration refers to an M score evolution that is lower than the R score evolution. Improvement indicates scores of patients that were lower at the end of the study than upon inclusion. Failure means degradation, and success is equal to the sum of deceleration and improvement. M, treatment with GEMSP; R, worldwide reference .  1  2  3  4  5  6   9  10  11  12  13  14  15  16   19  20  21  22  23  24  25  26   29  30  31  32  33  34  35  36   39  40  41  42  43  44  45  46   49  50  51  52  53  54  55  56   59  60   61  62  63  64  65  66   69   90  91  92  93  94  95  96   99  100  101  102  103  104  105  106   109  110  111  112  113  114  115  116 119 120
Evolution depending on the score upon inclusion. A statispercentages of success and failure for the EDSS scores 3-6 is, success (59.1%) and failure (40.9%). For patients with an (30%), deceleration (60%) and degradation (10%); that is, success (90%) and failure (10%). Thus, the three groups ( Fig. 2B-D) .
Discussion
Approved MS treatments are focused towards the the treatment of MS act against inflammatory processes.
including the progressive phases, is required (5) . Endotherapia takes into consideration environmental, immunological and MS and amyotrophic lateral sclerosis). Therefore, GEMSP (the therapeutic agent contains fatty acids), as well as for myelin/neuron protection (1, 12) . GEMSP contains compounds (e.g., vitamins), which are effective against nitrosative and
The linkage of heterogeneous molecules (e.g., amino acids, vitamins and fatty acids) to PLL offers various advantages as dation of the linked molecules; improvement of the kinetics, on the score at inclusion.
Parameter
Inclusion Furthermore, in GEMSP, the different molecules are linked to interactions and facilitates access to the lesion site) (13) . The are linked to PLL, since free constituents (not linked to PLL) are less active against MS symptoms and it seems that these free molecules either degrade or are rapidly incorporated into / -/ compound of the GEMSP (methionine) was located in the mechanisms (11). Furthermore, in a chronic EAE model, it was demonstrated that GEMSP protected and enhanced formation of the myelin sheath (14). In a phase IIa trial, 22 patients / patients did not react to the GEMSP treatment. No side effects /kg, single /day showed a worsening of their state; 20% showed a decrease in the progression of the disease; 35% showed an improvement patients showed a positive evolution of the disease (6) . The study results, with 22 and 102 patients, that were previously positive effect of treatment with GEMSP differs depending on the initial EDSS score of the patients. Thus, with a higher previous study performed in 102 patients (6) , the percentages MS patients of the latter study are included in the present work treatment increased from 26 to 40.9% and that the improve-(40.9 and 41%). Regarding the group in which the initial EDSS from 40 to 60% and the improvement was similar in the two studies (33 and 30%). Compared with other therapeutic agents, treatment with treatment with GEMSP in the present study, as the former for this reason, the clinical trials performed to date have shown therapeutic strategies (e.g., -interferon and glatiramer tant (16). In GEMSP, the presence of vitamins and certain amino acids and their derivatives (alpha-tocopherol-succinate, tant neuroprotective components and radical scavengers, -Alpha-tocopherol and neurotransmitters, such as histamine fatty acids (19, 20) . GEMSP protects and enhances the formathe fatty acids present in GEMSP are involved in the process Additionally, it is known that the oleic acid, present in GEMSP, acts as a neurotrophic factor in neurons (22) and that fatty 
